
# **Dabur India Limited**

#### **Investor Communication**

**Quarter and Half Year ended September 30, 2013** 



October 28, 2013


# Performance Overview: Q2 FY2013-14




- > Consolidated Net Sales grew by 14.9% to Rs. 1,748.8 crores
- > Consolidated EBITDA increased by 23.7% to Rs. 351.8 crores in Q2FY14.
- ➤ EBITDA margins improved by 144 bps on account of expansion in gross margins
- ➤ Consolidated PAT reported an increase of 23.4% to Rs. 249.7 crores
- > Interim Dividend of Re 0.75 per share

# **Financial Performance: Q2 FY14**






Consolidated sales grew by 14.9% with volume growth of 10.9%




➤ EBITDA margin expanded to 20.1% v/s 18.7% in Q2FY13 supported by lower material costs




➤ PAT growth of 23.4% with PAT Margins improving to 14.3% as compared to 13.3% in previous year

### **Financial Performance: H1 FY14**






Consolidated sales grew by 13.9% with volume growth of 10.7%




➤ EBITDA margin expanded to 18.3% vs 17.4% in H1FY13 supported by lower material costs



Consolidated PAT reported growth of 23.9% and PAT Margins improved to 12.8% from 11.8% in H1FY13

# **Dabur: Quarterly Sales Trend**






Steady trend in sales over last 10 quarters

# **Dabur: Quarterly PAT Trend**



#### **Dabur Consolidated Profit After Tax**


in Rs. crores




# Similar PAT trend over last 10 quarters with PAT almost touching Rs.250 crore

# **Business Overview – Q2 FY14**





#### **Domestic and International Sales Growth Rates**





Note: International includes Namaste and Hobi

- ➤ Domestic FMCG business comprising Consumer care and Foods reported growth of 14.4% in Q2FY14
- ➤ International Business grew by 25.8% in Q2FY14
- ➤ Others consisting of commodity exports registered some decline due to softening international prices


## **Business Overview - H1 FY14**







#### **Domestic and International Sales Growth Rates**




Note: International includes Namaste and Hobi

- ➤ Domestic FMCG business reported growth of 13.8% in H1FY14
- > International Business grew by 21.7% in H1FY14
- > Others consisting of commodity exports registered decline


### **Consumer Care Business**



#### **Consumer Care Category Growth Rates (%)**



#### **Category Contribution (H1FY14)**



#### **Highlights**

- ➤ Health Supplements grew well at 16.8% in Q2FY14
- ➤ Home Care reported robust growth at 25.3% during Q2FY14
- ➤ Oral Care grew by 18.7% driven by both toothpastes and toothpowders
- ➤ Skin Care grew well at 17.4% in Q2FY14

# **Health Supplements**



- ➤ Health Supplements grew by 16.8% in Q2FY14 driven by strong growth in Dabur Honey.
- Initial offtakes in Dabur Chyawanprash have been encouraging although the main season begins in third quarter.



Chyawanprash: Madhuri Dixit as the new brand ambassador



**Honey: Print Campaign** 

# **Digestives**



- ➤ Digestives category grew at 11.9% with the Hajmola franchise performing well
- Recently launched Anardana variant received good consumer response
- Pudin Hara performed well supported by media activities and launch of PH Lemon Fizz




**Pudin Hara: Launch of PH Lemon Fizz** 

## **OTC & Ethicals**



➤ OTC & Ethicals portfolio grew by 11.2% in Q2FY14 driven by strong growth of 18.1% in Ethicals Portfolio

#### OTC v/s Ethicals Sales Split (H1FY14)











**Ethicals: Rejuvenated Packing** 

### **Hair Care**



- ➤ Hair Care portfolio reported subdued growth due to high base and slow down in hair oil category
- Shampoo portfolio grew in double digits
- ➤ New products along with refurbished marketing mix expected to drive growth going ahead



Vatika: Launch of VAHO with Hibiscus

### **Home Care**



- ➤ Home Care grew at a robust 25.3% in Q2FY14 riding on strong growth in Odonil
- Odonil re-launched with 2x perfume content
- > Sanifresh continued its strong growth trend during the quarter



**Odonil: Relaunched with 2X freshness** 

### **Skin Care**



- ➤ Skin Care reported 17.4% growth in Q2FY14 with good performance of Fem portfolio
- Fem Bleaches grew well and witnessed gains in market share
- Gulabari witnessed robust growth backed by media activities



OxyLife Men: Entry into male grooming segment





**Gulabari: New Communication** 

## **Oral Care**



- ➤ Oral Care grew by 18.7% in Q2FY14 with both toothpastes and toothpowder reporting strong growth
- Red Toothpaste continued to be the star performer and gained market share



LDM: Ravi Kishen TVC with "9cr bhartiyon ka bharosa"

# **Foods**



- Foods continued its strong growth trend with 22% growth in Q2FY14
- > Saliency of Real fruit juices in rural witnessed improvement
- > Innovation and distribution expansion driving growth




Real: Milk Shakes Test Launched in Delhi and Punjab

### **International Business**



- International Business grew by 25.8% in Q2FY14 with constant currency growth of 13.8%.
- Organic International Business reported strong growth in MENA and Bangladesh
- Namaste business continued on the recovery path and witnessed double digit growth in USD terms
- ➤ Hobby business grew in double digits in constant currency terms



<sup>\*</sup> Growth in constant currency terms

# **International Business – New Launches**





Vatika – Brillantine Shine



Vatika Hair Gel – New Lamitubes



Amla Shampoo Range



**Amla Conditioners Range** 

# **Consolidated P&L (Published)**



| DIL (Consolidated) P&L - in Rs. crores         | Q2FY14  | Q2FY13  | YoY (%) | H1FY14  | H1FY13  | YoY (%) |
|--|---------|---------|---------|---------|---------|---------|
| Net Sales                                      | 1,748.8 | 1,522.6 | 14.9%   | 3,399.9 | 2,984.6 | 13.9%   |
| Other Operating Income                         | 5.4     | 4.9     | 9.8%    | 10.8    | 14.7    | -26.1%  |
| Material Cost                                  | 807.2   | 752.5   | 7.3%    | 1614.6  | 1484.1  | 8.8%    |
| % of Sales                                     | 46.2%   | 49.4%   |         | 47.5%   | 49.7%   |         |
| Employee Expense                               | 158.8   | 128.6   | 23.5%   | 296.8   | 240.5   | 23.4%   |
| % of Sales                                     | 9.1%    | 8.4%    |         | 8.7%    | 8.1%    |         |
| Advertising & Publicity                        | 227.4   | 180.8   | 25.8%   | 481.7   | 410.0   | 17.5%   |
| % of Sales                                     | 13.0%   | 11.9%   |         | 14.2%   | 13.7%   |         |
| Other Expenses                                 | 231.5   | 205.5   | 12.7%   | 454.3   | 392.6   | 15.7%   |
| % of Sales                                     | 13.2%   | 13.5%   |         | 13.4%   | 13.2%   |         |
| Other Non Operating Income                     | 22.6    | 24.3    | -7.1%   | 59.2    | 46.8    | 26.6%   |
| EBITDA   | 351.8   | 284.4   | 23.7%   | 622.6   | 518.8   | 20.0%   |
| % of Sales                                     | 20.1%   | 18.7%   |         | 18.3%   | 17.4%   |         |
| Finance Costs                                  | 20.0    | 14.9    | 34.2%   | 33.3    | 36.1    | -7.9%   |
| Depreciation & Amortization                    | 23.6    | 19.6    | 20.6%   | 45.6    | 40.6    | 12.3%   |
| Profit Before Tax (PBT)                        | 308.3   | 250.0   | 23.3%   | 543.7   | 442.1   | 23.0%   |
| Exceptional Item                               | 0.0     | 0.0     |         | 0.0     | -4.7    |         |
| Tax Expenses                                   | 57.9    | 46.4    | 24.6%   | 106.3   | 84.2    | 26.2%   |
| PAT(Before extraordinary item)                 | 250.4   | 203.6   | 23.0%   | 437.4   | 353.2   | 23.8%   |
| % of Sales                                     | 14.3%   | 13.4%   |         | 12.9%   | 11.8%   |         |
| Extraordinary Item                             | -0.1    | 0.1     | -210.6% | -0.1    | 0.1     |         |
| PAT(After extraordinary Items)                 | 250.3   | 203.7   | 22.9%   | 437.4   | 353.3   | 23.8%   |
| Minority Interest - Profit/(Loss)              | 0.6     | 1.3     |         | 1.6     | 1.5     |         |
| PAT (After Extra ordinary item & Minority Int) | 249.7   | 202.4   | 23.4%   | 435.7   | 351.8   | 23.9%   |
| % of Sales                                     | 14.3%   | 13.3%   |         | 12.8%   | 11.8%   |         |

# **Consolidated Statement of Assets and Liabilities**



| Particulars                         | As at 30/09/2013 | As at 31/03/2013 |  |
|-------------------------------------|------------------|------------------|--|
| 2 W 120 W 2                         | (Audited)        | (Audited)        |  |
| À EQUITY AND LIABILITIES            |                  | ,                |  |
| 1 Shareholders' funds               |                  |                  |  |
| (a) Share capital                   | 174.4            | 174.3            |  |
| (b) Reserves and surplus            | 2,177.9          | 1,950.1          |  |
| •                                   |                  |                  |  |
| Sub-total - Shareholders' funds     | 2,352.3          | 2,124.4          |  |
| 2. Minority interest                | 15.3             | 12.1             |  |
| 3. Non-current liabilities          |                  |                  |  |
| (a) Long-term borrowings            | 517.7            | 539.9            |  |
| (b) Deferred tax liabilities (net)  | 44.9             | 36.2             |  |
| (c) Other long-term liabilities     | 0.1              | 0.1              |  |
| (d) Long-term provisions            | 48.3             | 48.8             |  |
| Sub-total - Non-current liabilities | 611.1            | 625.1            |  |
| 4. Current liabilities              |                  |                  |  |
| (a) Short-term borrowings           | 544.2            | 611.4            |  |
| (b) Trade payables                  | 1,047.7          | 745.3            |  |
| (c) Other current liabilities       | 383.1            | 432.0            |  |
| (d) Short-term provisions           | <i>17</i> 8.9    | 186.9            |  |
| Sub-total - Current liabilities     | 2,154.0          | 1,975.6          |  |
| TOTAL - EQUITY AND LIABILITIES      | 5,132.6          | 4,737.1          |  |
| B ASSETS                            |                  |                  |  |
| 1. Non-current assets               |                  |                  |  |
| (a) Fixed assets                    | 1,133.8          | 1,053.0          |  |
| (b) Goodwill on consolidation       | 621.4            | 621.4            |  |
| (c) Non-current investments         | 346.7            | 233.2            |  |
| (d) Long-term loans and advances    | 12.6             | 15.8             |  |
| (e) Other non-current assets        | 59.9             | 217.7            |  |
| Sub-total - Non-current assets      | 2,174.4          | 2,141.1          |  |
| 2 Current assets                    |                  |                  |  |
| (a) Current investments             | 682.7            | 650.4            |  |
| (b) Inventories                     | 948.4            | 843.9            |  |
| (c) Trade receivables               | 688.1            | 484.1            |  |
| (d) Cash and cash equivalents       | 343.6            | 356.8            |  |
| (e) Short-term loans and advances   | 216.4            | 201.5            |  |
| (f) Other current assets            | 79.1             | 59.3             |  |
| Sub-total - Current assets          | 2,958.3          | 2,596.1          |  |
| Total -Assets                       | 5,132.6          | 4,737.1          |  |

#### **Disclaimer**



Some of the statements made in this presentation contain forward looking information that involve a number of risks and uncertainties. Such statements are based on a number of assumptions, estimates, projections or plans that are inherently subject to significant risks, as well as uncertainties and contingencies that are subject to change. Actual results can differ materially from those anticipated in the Company's forward-looking statements as a result of a variety of factors, including those set forth from time to time in the Company's press releases and reports and those set forth from time to time in the Company's analyst calls and discussions. We do not assume any obligation to update the forward-looking statements contained in this presentation.

No part of this presentation shall form the basis of or may be relied upon in connection with any contract or commitment. This presentation is being presented solely for your information and is subject to change without notice.



# Thank You